Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here

Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

Bookmark and Share
Constantly updated health news, click here.
Links to HIV/AIDS resources and articles published by MJoTA since 2007 click here.
Diabetes resources, click here
Asthma resources, click here
HIV/AIDS. SJ Dodgson MJoTA 2013 v7n2 p1203

When I was laying out pages on Zambia and the Peace Corps, I came across a disturbing story of a returned Peace Corps volunteer who was in Zambia for less than 3 months when she was diagnosed with HIV infection, and sent back to the United States.

She had met a man and said she only had sex with him once. She did not believe that she had sex with him more than that, although she admitted before she finally decided she was comfortable enough with him to have "sex" she had orally satisfied him on two occasions. Taking his body fluids into her mouth. That is sex, and that is dangerous.

I have been looking through the scientific literature which is surprisingly silent on the risk of HIV infection through orally satisfying a man. Is the risk low? High? I don't care. The risk is there.

Don't orally satisfy a man without using a condom. Or anally satisfy. Or vaginally satisfy. Or exchange body fluids. If you are tied to him by a short string for months, years, or live on a small island with no access to the outside world (or condoms), or both are eager for children, you can not use a condom.

Of course, any insistence on stepping away or rigorous condom use on a woman's part can only be accepted if the woman has the power to say no. Peace Corps workers do have that power. So does every woman in the United States.

HIV Therapies. SJ Dodgson. The Journal of the European Medical Writers Association. 2003. v12.

I first heard of the HIV epidemic in the summer of 1981 when I was listening to the radio while bathing my first-born child in the kitchen sink in my apartment in Philadelphia. The Centers for Disease Control reported a strange epidemic in homosexual men, later, the risk group included Haitians, still later, intravenous drug users and now, whole African countries like Botswana. As the years passed, the main risk groups changed and life-prolonging medications have become available in rich, industrialized countries. One theme remains constant: AIDS is a deadly disease and infected persons can become resistant to all the therapies.

Two gay men living next-door to me in Sydney when I was finishing my PhD thesis are gone. I visited them when I went back to Sydney with my children in 1982 and 1983, we discussed day-to-day events and our futures as if I had never left.

For me, HIV/AIDS is about two young men, friends since kindergarten, who never reached 50, or even 40. And especially about Ian, who was gorgeous looking and loved by many men. Ian made dresses and cooked for us and learned Italian so he could teach in Italy but instead with good grace taught English in Turkey where he was sent by the New South Wales Department of Education. Graeme was monogamous and left teaching to work in the phone company. He didn’t reach 40 either.

During the early years of the epidemic I was involved in investigating carbon dioxide handling in the body. I identified mechanisms of carbon dioxide fixing and releasing in the liver, kidney, and brain and confirmed that these mechanisms work in neutrophils, which are involved in the immune system. Do they also work in CD4+ cells? Probably. I can state confidently that therapeutically disrupting the carbon dioxide handling mechanisms of the immune cells that the HIV virus hijacks has never been under serious consideration. The HIV virus is tough and when its DNA takes over a CD4+ cell, what it does is reproduce virus and destroy the ability of the body to defend itself against bacteria, fungi, other viruses and cancer. The virus rapidly evolves and rapidly can become resistant to one treatment after another.

I started full-time writing about HIV a week after the devastating cascade of events that started when 2 passenger airlines smashed themselves between upper floors of 20% of New York City office-space.

The immediate consequences of these smashes and the 2 following in Pennsylvania and Washington DC was a scaling-back of marketing writing in the center of the pharmaceutical industry, which is surrounded geographically by New York City, Pennsylvania, Washington DC and the Atlantic Ocean.

The immediate consequence to me was that within a week, the disease monographs I was writing for an advertising agency were no longer needed and a medical communications company needed a medical writer who would travel by air for their client in California.

Ten days later, I flew to southern California for a consultant meeting. The next morning the account executive drove us both north along the coast of California, past Los Angeles, to Santa Barbara to a resort, which were arguably my most luxurious accommodations. I enjoyed walking past the oleander and rhododendrons before diving into a swimming pool, then hanging out in a hot tub before bathing in my room while watching candles in the fireplace and the palm trees over the balcony at the same time. After listening to talks about the treatment of HIV from a psychiatrist, an HIV resistance specialist and a lipodystrophy specialist. The meals were terrific too.

The work with the medical communications company only improved. On the heels of the conferences in California was the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. A meeting with the client in Santa Barbara revealed their desire to have a presence at the meeting in Athens as well as their reluctance to send any of their own employees.

I think the whole September 11 disaster was easier on those of us who were in the middle of it; we saw what happened and we saw it being cleaned up.

Three thousand miles away in California all they knew was that all of the 4 passenger airliners that crashed were headed for California. I was not quiet about my desire to represent my favorite pharmaceutical company and report on the Athens meeting and so, two weeks later, I stepped off a plane in Athens.

The need for an annual lipodystrophy conference since 1999 highlights the consequences of taking drugs to control HIV infection. The first two classes of HIV drugs are retroviral inhibitors: the nucleotide retroviral inhibitors (NRTIs) and the non-nucleotide retroviral inhibitors (NNRTIs). The first drug with any controlling effect on HIV is known as AZT or ZDV or zidovudine. AZT was approved by the US Food and Drug Administration in 1987, since then other NRTIs have been approved and this class remains the largest. The approval of a third group of HIV drugs in 1995, the protease inhibitors, was earth-shaking for those affected with HIV and those treating affected persons. For the first time, health care providers were not routinely burying their infected patients.

Since 1995 the treatment of choice is a drug cocktail, called by the US Department of Health and Human Services Highly Active Anti-Retroviral Therapy, or HAART. This cocktail includes 3 or 4 drug cocktails from one or more classes. Since 1995, persons infected with HIV on HAART are living longer, but those infected are still at risk for premature death.

In the 1980s, HIV infection meant that death from AIDS probably would follow within 5 to 10 years. In the past few years, persons infected with HIV and treated with HAART have had increased likelihood of cardiovascular events. The question about whether the cardiovascular events result from the HIV infection or from HAART drugs remains unanswered.

In May I sent daily reports from Digestive Disease Week in San Francisco, summarizing talks on treatments for hepatitis C and HIV co-infection. The rate of co-infection is increasing, and liver failure is now the number 1 cause of death of persons infected with HIV.

The 14th International AIDS Conference in Barcelona in July was huge and all the pharmaceutical companies were well-represented. I summarized 12 symposia in which consultants presented the industry’s newest therapies. We heard about progress towards producing a viable anti-HIV vaccine. We are not yet there, but clinical trials are proceeding and within 12 months we will know if one or more vaccines are fulfilling their early promise. Other classes of anti-HIV drugs were described, the fusion inhibitors which prevent the HIV virus from inserting its DNA into CD4+ cells and the integrase inhibitors, which prevent reproduction of the virus inside the CD4+ cell.

The most exciting part of the conference to me was sitting next to infected persons who would have been dead 10 years ago. The bottom line is that Ian and Graeme would have had a good possibility of living to 40, or 50 if they had been infected 10 years later.

I was sitting in the hot-tub in Santa Barbara in October 2001, chatting with 2 HIV physicians about the oil I had tracked from the beach into the bath-tub. I assumed that the oil resulted from some tanker spill somewhere; one of the physicians told me that the oil pre-dated settlement by Europeans, and that native Americans used it to water-proof boats. These boats were leaky and the trick was to land somewhere before the boats were swamped.

Which describes HIV therapies. HIV is a tricky disease to treat because infected persons either do not have access to treatment (a major problem in developing countries) or they can become resistant to one treatment after another. All we can hope for anyone infected is that they can stay afloat until they reach land.

This essay was first published by the European Medical Writers Association in 2003 in The Write Stuff.

Mr Amadou Diagne. SJ Dodgson. MJoTA 2012 v6n1 p0412

The man from Gilead Pharmaceutical Company was at the African Caribbean Business Council Forum today, Apr 12, 2012, giving his talk about the threat and treatment of HIV/AIDS.

He is Mr Amadou Diagne, Associate Director, Medical Sciences, at Gilead Sciences Inc.

I have now heard him 4 times, in New York, Pennsylvania and New Jersey, and seen him at other African community events. He is passionate about preventing HIV/AIDS in African Diaspora communities, and he told me today he has had feedback from several who had not known they were infected, but sought testing and treatment after listening to him.

Ah, as I told him, and also Philadelphia's wonderful Ghanaian foot doctor and educator (he started schools in Accra and Philadelphia, and inducts Ghanaian Queens and Kings), Dr Samuel Quartey: if only drug companies selling high blood pressure medicines and diabetes medicines would sponsor health professionals to aggressively seek out African communities to warn against cardiovascular disease.

Cardiovascular disease is killing more adults in African communities than HIV/AIDS.

HIV/AIDS prevention and treatment of HIV infection is working, because it could easily have become the number one killer. Before antiretroviral drugs and the Herculean efforts of President Bill Clinton and other former country politicians, HIV infection was set to be the main killer, click here.

HIV/AIDS resources click here.
December 1st: World AIDS Day. Remembering the millions killed by this disease, and the enormous advances in medical science that have resulted in HIV/AIDS being treated as a chronic disease. If you have the drugs, and you take them every time you are meant to, you can live a normal life span. Make your life count, so many have died, and are dying, without access to HIV/AIDS medicines and healthcare.
Below are articles from a continuous feed from the CDC, which is the United States Department of Health Centers for Disease Control and Prevention. They are the largest health data gathering organization on the planet.

Latest Top (20) News

Social Determinants of Health among Adults with Diagnosed HIV Infection in 13 States, the District of Columbia, and Puerto Rico, 2015
A new HIV Surveillance Supplemental Report focuses on census tract-level social determinants of health (SDH) among adults with HIV infection diagnosed in 2015 in 11 U.S. states, the District of Columbia, and Puerto Rico. The SDH variables examined are: percentage of the population living below federal poverty, percentage of the population with less than a high school diploma, median household income, percentage of the population unemployed, percentage of residents without health insurance coverage, and new to this report, percentage of vacant housing unit. This report presents a snapshot of the environment in which people lived at the time of HIV diagnosis.

Tue, 15 Aug 2017 11:05:00 EDT

Recommendations for HIV Screening of Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2017
CDC concludes that the evidence, programmatic experience, and expert opinions are insufficient to warrant changing the current recommendation (annual screening for MSM) to more frequent screening (every 3 or 6 months). Therefore, CDC’s 2006 recommendation for HIV screening of MSM is unchanged; providers in clinical settings should offer HIV screening at least annually to all sexually active MSM. Clinicians can also consider the potential benefits of more frequent HIV screening (e.g., every 3 or 6 months) for some asymptomatic sexually active MSM based on their individual risk factors, local HIV epidemiology, and local policies.

Fri, 11 Aug 2017 09:30:00 EDT

Learn About the HIV Screening. Standard Care. Campaign.
The HIV Screening. Standard Care.TM (HSSC) program educates primary care clinicians about the importance of making HIV screening a routine part of care. The HSSC website provides clinicians and patients with free materials and continuing education opportunities, as well tools and other resources for implementing HIV screening.

Tue, 8 Aug 2017 11:15:00 EDT

Syringe Services Program Info Sheet
Syringe Services Program (SSP) which have also been referred to as syringe exchange programs (SEPs), needle exchange programs (NEPs) and needle-syringe programs (NSPs) are community-based programs that provide access to sterile needles and syringes free of cost and facilitate safe disposal of used needles and syringes.

Thu, 3 Aug 2017 14:00:00 EDT

Continuum of Care
Learn about CDC’s approach to HIV prevention, state and national progress toward meeting national HIV prevention goals, and laws and policies that affect HIV prevention and care activities.

Wed, 2 Aug 2017 14:30:00 EDT

Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data United States and 6 Dependent Areas, 2015
HIV Surveillance Supplemental Report that provides updates on progress towards achieving national HIV prevention and care goals.

Thu, 27 Jul 2017 10:00:00 EDT

Selected National HIV Prevention and Care Outcomes
The slide set provides graphical representations of some of the care outcome data in the report, Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data - United States and 6 Dependent Areas, 2015.

Thu, 27 Jul 2017 09:55:00 EDT

HIV in the US Continuum of Care Infographic
This infographic shows the continuum of HIV care for people living with HIV in the United States.

Thu, 27 Jul 2017 09:50:00 EDT

Selected National HIV Prevention and Care Outcomes in the United States Fact Sheet
This fact sheet describes a subset of national indicators that are steps in the HIV care continuum and are used to monitor progress toward national goals in the United States.

Thu, 27 Jul 2017 09:45:00 EDT

Understanding the HIV Care Continuum Fact Sheet
This fact sheet explains the various approaches and data used to develop the HIV care continuum, how it is used to improve outcomes for people living with HIV in the United States and how it helps guide the nation’s response to HIV.

Thu, 27 Jul 2017 09:40:00 EDT

CDC Funded HIV Testing United States Puerto Rico and US Virgin Islands
The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates data on CDC-funded HIV testing. HIV test event-level data are reported by CDC grantees through the National HIV Prevention Program's Monitoring and Evaluation system.

Wed, 12 Jul 2017 15:30:00 EDT

Integrated HIV Surveillance and Prevention Funding for Health Departments
The Centers for Disease Control and Prevention (CDC) has renewed and strengthened its flagship funding program to support HIV surveillance and prevention efforts led by health departments in states, territories, and selected counties and cities. This new funding opportunity – which integrates CDC’s HIV surveillance and prevention programs for the first time – is the agency’s largest single investment in HIV surveillance and prevention and will be the cornerstone of national prevention efforts for the next five years.

Thu, 06 Jul 2017 10:00:00 EDT

PS18-1802: Integrated HIV Surveillance and Prevention Programs for Health Departments
The purpose of this funding opportunity announcement is to implement a comprehensive HIV surveillance and prevention program to prevent new HIV infections and achieve viral suppression among persons living with HIV.

Wed, 28 Jun 2017 09:00:00 EDT

CDC Observes National HIV Testing Day
June 27, 2017 is National HIV Testing Day, which promotes the importance of HIV testing to increase the number of people who are aware of their HIV status. Learn more about the awareness day and download materials to support it.

Tue, 27 Jun 2017 07:30:00 EDT

Dear Colleague: National HIV Testing Day
June 27, 2017 is National HIV Testing Day, which promotes the importance of HIV testing to increase the number of people who are aware of their HIV status. Learn more about the latest research and what CDC is doing to increase HIV testing.

Mon, 26 Jun 2017 11:00:00 EDT

New HIV Testing Technologies: Implications for your Laboratory
Since CDC and APHL recommended a new test algorithm for laboratory diagnosis of HIV infection in 2014, new HIV tests have received approval for use in the US. This intermediate-level presentation will review the 2014 recommended algorithm, newly approved HIV test technologies and their implications for the algorithm. Potential challenges and opportunities that these new technologies create for your laboratory will be discussed.

Mon, 30 May 2017 17:15:00 EDT

State Health Profiles
The updated state health profiles present an overview of the burden of HIV/AIDS, viral hepatitis, STDs, and TB in the United States, all 50 states, and Washington, D.C. The profiles present the latest nationally representative data, as well as information about prevention and control programs that CDC supports nationally and in each state.

Fri, 26 May 2017 10:30:00 EDT

Diagnosed HIV Infection among Adults and Adolescents in Metropolitan Statistical Areas–United States and Puerto Rico, 2015
The report supplements the 2015 HIV Surveillance Report and presents data on diagnoses of HIV infection during 2015 and on persons living with diagnosed HIV infection at year-end 2014 (prevalence) for adults and adolescents (aged 13 years and older) residing in metropolitan statistical areas (MSAs, population of 500,000 or more) in the United States and Puerto Rico.

Thu, 25 May 2017 12:00:00 EDT

Behavioral and Clinical Characteristics of Adults Receiving HIV Medical Care Medical Monitoring Project 2014 Cycle (June 2014 – May 2015)
This slide set presents estimates of behavioral and clinical characteristics of adults receiving HIV medical care in the US during 2014 using information from the Medical Monitoring Project (MMP).

Tue, 23 May 2017 11:00:00 EDT

HIV Among Asians in the United States
This fact sheet contains information and statistical data about HIV among Asians.

Mon, 09 May 2017 09:00:00 EDT
Writing About HIV/AIDS
Nelson Mandela joined hands with Bill Clinton to get free meds to HIV infected throughout Africa. Enormous achievement. I saw them both talk about it at the International AIDS Conference in Barcelona in 2002.

The International AIDS Conference mees every 2 years; the 2000 meeting was in South Africa, where odd things had been said about infection and treatment by senior South African politicians. Mr Mandela was already out of office, but gave the closing address.

In 2002 I was working as a freelance medical writer for ADIS International, which was contracted by Pfizer to write about treatment for HIV infection. The closing ceremony was in a huge stadium that had been constructed for the 1992 Olympic Games. The stadium was jammed with an enthusiastic audience.

Mr Clinton spoke first, and then Mr Mandela. They spoke of human rights and the right of every human to get access to treatment for HIV infection. Very warmly, very firmly.

And they made it happen.

In Jan 2005, 30 months later, the death of Nelson Mandela's oldest son was reported. A brilliant lawyer, he died from HIV/AIDS.